New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2014
08:31 EDTTEVA, PFETeva announces launch of authorized generic Detrol
Teva Pharmaceutical Industries (TEVA) announced today the launch of the authorized generic of Detrol LA 2 mg and 4 mg in the U.S. market. Detrol LA had annual sales of approximately $571.5M in the U.S., according to IMS data as of September 30, 2013. Detrol is a registered trademark of Pfizer Enterprises Sarl (PFE).
News For TEVA;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
16:00 EDTPFEOptions Update; May 29, 2015
Subscribe for More Information
08:32 EDTTEVATeva launches generic Lomedia 24 Fe tablets
Teva announces the launch of the generic equivalent of Lomedia 24 Fe as part of the extensive line of Women’s Health products. The product will be launched under the name Junel Fe 24 and is now available in the United States. Lomedia 24 Fe marketed by Amneal had annual sales of approximately $32M in the United States, according to IMS data as of December 2014. Junel Fe 24 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
08:31 EDTPFEPfizer says FDA approves Rapamune for treatment of LAM
Subscribe for More Information
May 28, 2015
16:34 EDTPFEFDA approves Pfizer's Rapamune to treat LAM
Subscribe for More Information
15:30 EDTPFECellectis in takeover talks with Pfizer named as suitor, FT reports
Subscribe for More Information
10:52 EDTPFEPfizer to host conference call
Subscribe for More Information
09:07 EDTTEVAFTC, Teva reach $1.2B settlement over Provigil
Subscribe for More Information
09:00 EDTPFEPfizer has 'significant capacity' for additional deals, says JPMorgan
Subscribe for More Information
08:55 EDTTEVAXenon Pharmaceuticals sees IND for phase 1 trial of XEN801 in mid-2015
Xenon Pharmaceuticals (XENE) announced that Dr. Simon Pimstone, Xenon's President and CEO, will present a business update, including progress toward milestones, at the Jefferies Global Healthcare Conference on Tuesday, June 2. Xenon's partner Teva Pharmaceutical (TEVA) is conducting a randomized, double-blind, placebo-controlled Phase 2b clinical trial for TV-45070 in osteoarthritis. Results from the trial are now expected late in the second quarter or early in the third quarter of 2015. Xenon's partner Genentech, a member of the Roche Group (RHHBY), is currently conducting a Phase 1 clinical trial for GDC-0276, which is expected to complete patient enrollment in the second half of 2015. Xenon expects to file an investigational new drug equivalent application to initiate a Phase 1 clinical trial of XEN801, a stearoyl Co-A desaturase or SCD1 inhibitor for treatment of acne, in mid-2015. If supported by positive data from the Phase 1 trial, Xenon plans to initiate a proof-of-concept Phase 2 clinical trial in the second half of 2015. Xenon expects to file an investigational new drug application for Xenon's Nav1.6 sodium channel inhibitor for Dravet Syndrome in 2016.
08:33 EDTPFEPfizer announces $3M grants program to further research in breast cancer
Subscribe for More Information
06:11 EDTTEVATeva takes 1.35% stake in Mylan, says 'ready to meet' on deal
Subscribe for More Information
May 27, 2015
12:10 EDTTEVATeva to sweeten offer for Mylan before July shareholder vote, NY Post says
Subscribe for More Information
08:24 EDTTEVAFDA reports paragraph IV patent challenge received for Treanda
Subscribe for More Information
May 26, 2015
14:07 EDTPFEFDA approves request for updated package insert for Prevnar 13
The FDA approved a request from Pfizer's Wyeth Pharmaceuticals to supplement the biologics license application for Pneumococcal 13-valent Conjugate Vaccine, or Prevnar 13, to update the package insert to include data from the CAPiTA confirmatory efficacy study in adults. Reference Link
May 22, 2015
10:52 EDTPFEJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
07:37 EDTPFEPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
07:46 EDTPFEDeutsche Bank positive on potential Pfizer, GSK merger
Deutsche Bank analyst Gregg Gilbert believes a large foreign deal for Pfizer (PFE) may make sense and says a buyout of GlaxoSmithKline (GSK) could be "materially" accretive to earnings while improving the company's tax situation over time. Gilbert assumes a $60 per share buyout price for GlaxoSmithKline in a research note this morning titled "Introducing 'PfizerKline'". The stock closed yesterday up 2c to $44.68. Gilbert reiterates a Buy rating on Pfizer with a $41 price target. Shares ended yesterday up 23c to $34.21.
May 19, 2015
06:55 EDTPFEGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
06:08 EDTTEVAPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
May 18, 2015
06:58 EDTPFEActavis CEO says chances of Pfizer offer are 'unlikely', Financial Times says
Actavis (ACT) CEO Brent Saunders said the chances of Pfizer (PFE) making an offer are "incredibly unlikely," reports the Financial Times. Saunders said he has heard the gossip that Actavis could become a takeover target for a larger group, but he spends "zero time thinking about it." Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use